These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 34944799)

  • 1. Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers.
    Gracia-Hernandez M; Munoz Z; Villagra A
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
    Yeon M; Kim Y; Jung HS; Jeoung D
    Front Cell Dev Biol; 2020; 8():486. PubMed ID: 32626712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
    Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
    Front Immunol; 2021; 12():661737. PubMed ID: 34025662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies.
    Rubanov A; Berico P; Hernando E
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Current and Pipeline Drugs for Treatment of Melanoma.
    Natarelli N; Aleman SJ; Mark IM; Tran JT; Kwak S; Botto E; Aflatooni S; Diaz MJ; Lipner SR
    Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies".
    Strub T; Ballotti R; Bertolotto C
    Theranostics; 2020; 10(4):1777-1797. PubMed ID: 32042336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies.
    Rubatto M; Borriello S; Sciamarrelli N; Pala V; Tonella L; Ribero S; Quaglino P
    Melanoma Res; 2023 Dec; 33(6):462-474. PubMed ID: 37788101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy.
    Gallagher SJ; Tiffen JC; Hersey P
    Cancers (Basel); 2015 Sep; 7(4):1959-82. PubMed ID: 26426052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
    Kakavand H; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma.
    da Silveira Nogueira Lima JP; Georgieva M; Haaland B; de Lima Lopes G
    Cancer Med; 2017 Jun; 6(6):1143-1153. PubMed ID: 28463413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma Targeted Therapies beyond
    Khaddour K; Maahs L; Avila-Rodriguez AM; Maamar Y; Samaan S; Ansstas G
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34831002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
    Tang T; Eldabaje R; Yang L
    Anticancer Res; 2016 Jul; 36(7):3229-41. PubMed ID: 27354579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance.
    Wagstaff W; Mwamba RN; Grullon K; Armstrong M; Zhao P; Hendren-Santiago B; Qin KH; Li AJ; Hu DA; Youssef A; Reid RR; Luu HH; Shen L; He TC; Haydon RC
    Genes Dis; 2022 Nov; 9(6):1608-1623. PubMed ID: 36157497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
    Kiniwa Y; Okuyama R
    Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
    Deken MA; Gadiot J; Jordanova ES; Lacroix R; van Gool M; Kroon P; Pineda C; Geukes Foppen MH; Scolyer R; Song JY; Verbrugge I; Hoeller C; Dummer R; Haanen JB; Long GV; Blank CU
    Oncoimmunology; 2016; 5(12):e1238557. PubMed ID: 28123875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors in melanoma.
    Carlino MS; Larkin J; Long GV
    Lancet; 2021 Sep; 398(10304):1002-1014. PubMed ID: 34509219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.